Ridd Matthew J, Wells Sian, Edwards Louisa, Santer Miriam, MacNeill Stephanie, Sanderson Emily, Sutton Eileen, Shaw Alison R G, Banks Jonathan, Garfield Kirsty, Roberts Amanda, Barrett Tiffany J, Baxter Helen, Taylor Jodi, Lane J Athene, Hay Alastair D, Williams Hywel C, Thomas Kim Suzanne
Centre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK
Centre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK.
BMJ Open. 2019 Nov 6;9(11):e033387. doi: 10.1136/bmjopen-2019-033387.
Atopic dermatitis/eczema affects around 20% of children and is characterised by inflamed, dry, itchy skin. Guidelines recommend 'leave-on' emollients that are applied directly to the skin to add or trap moisture and used regularly, they can soothe, enhance the skin barrier and may prevent disease 'flares'. However, the suitability of the many different emollients varies between people and there is little evidence to help prescribers and parents and carers decide which type to try first.
Design: pragmatic, multicentre, individually randomised, parallel group superiority trial of four types of emollient (lotions, creams, gel or ointments).
general practitioner surgeries in England.
children aged over 6 months and less than 12 years with mild-to-severe eczema and no known sensitivity to study emollients.
study-approved lotion, cream, gel or ointment as the only leave-on emollient for 16 weeks, with directions to apply twice daily and as required. Other treatments, such as topical corticosteroids, used as standard care.
FOLLOW-UP: 52 weeks.
validated patient-orientated eczema measure measured weekly for 16 weeks.
eczema signs (Eczema Area Severity Index) by masked researcher, treatment use, parent satisfaction, adverse events, child and family quality of life (Atopic Dermatitis Quality of Life, Child Health Utility 9D and Dermatitis Family Impact).
520 participants (130 per group).
intention-to-treat using linear mixed models for repeated measures.Nested qualitative study: audio-recording of sample of baseline appointments and up to 60 interviews with participants at 4 and 16 weeks, interviews to be transcribed and analysed thematically.
Ethics approval granted by the NHS REC (South West - Central Bristol Research Ethics Committee 17/SW/0089). Findings will be presented at conferences, published in open-access peer-reviewed journals and the study website; and summaries shared with key stakeholders.
ISRCTN84540529.
特应性皮炎/湿疹影响着约20%的儿童,其特征为皮肤发炎、干燥、瘙痒。指南推荐使用“涂抹式”润肤剂,直接涂抹于皮肤上以增加或锁住水分,并定期使用,它们可以舒缓肌肤、增强皮肤屏障,还可能预防疾病“发作”。然而,众多不同润肤剂的适用性因人而异,几乎没有证据能帮助开处方者以及家长和护理人员决定首先尝试哪种类型。
设计:对四种类型的润肤剂(洗剂、乳膏、凝胶或软膏)进行实用、多中心、个体随机、平行组优效性试验。
英格兰的全科医生诊所。
年龄超过6个月且小于12岁、患有轻至重度湿疹且对研究用润肤剂无已知敏感性的儿童。
经研究批准的洗剂、乳膏、凝胶或软膏作为唯一的涂抹式润肤剂使用16周,指导为每日涂抹两次并按需使用。其他治疗,如局部用皮质类固醇,用作标准护理。
52周。
在16周内每周测量一次经验证的以患者为导向的湿疹指标。
由盲法研究人员评估的湿疹体征(湿疹面积和严重程度指数)、治疗使用情况、家长满意度、不良事件、儿童及家庭生活质量(特应性皮炎生活质量、儿童健康效用9D和皮炎家庭影响)。
520名参与者(每组130名)。
采用线性混合模型进行意向性分析以处理重复测量数据。嵌套定性研究:对基线预约样本进行录音,并在第4周和第16周对参与者进行多达60次访谈,并对访谈内容进行转录和主题分析。
获得了英国国家医疗服务体系研究伦理委员会(西南 - 布里斯托尔中部研究伦理委员会17/SW/0089)的伦理批准。研究结果将在会议上展示,发表在开放获取的同行评审期刊和研究网站上;并向主要利益相关者分享总结内容。
ISRCTN84540529。